Phase Genomics: David Shoultz
David Shoultz has been appointed as the first chief business officer of Phase Genomics. He comes to the Seattle-based firm from Monod Bio, a spinout from the Institute for Protein Design that he cofounded and where he served as chief operating officer. Previously, he was a member of the global health product development team at the Bill & Melinda Gates Foundation, directed the global drug development program at PATH, and held scientific leadership positions at Neoleukin Therapeutics and PPD (now part of Thermo Fisher Scientific).
QuidelOrtho: Jonathan Siegrist, Werner Kroll
QuidelOrtho has appointed Jonathan Siegrist as executive VP of R&D and chief technology officer. He succeeds Werner Kroll, senior VP of R&D, who will support the transition until his retirement in March. Siegrist was most recently chief technology officer and head of assay R&D at Cepheid. Prior to that, he cofounded iGlyko, a diagnostics manufacturing company. He will spearhead QuidelOrtho's R&D strategy, focusing on menu expansion and advancing critical platforms.
Inflammatix: Sam Ajizian, Jamie Lewis, Laura Spencer Garth
Inflammatix has appointed Sam Ajizian as chief medical officer, Jamie Lewis as chief commercial officer, and Laura Spencer Garth as general counsel. Ajizian previously served in multiple roles at Medtronic, including as chief medical officer for the firm's acute care and monitoring business. As Inflammatix prepares to launch its point-of-care TriVerity Test for the rapid assessment of infection type and severity, Ajizian will help to form a team of medical science liaisons to educate healthcare providers on the use of the test and the firm's Myrna real-time RT-LAMP instrument.
Lewis previously worked in leadership roles at Outset Medical and Intuitive Surgical. She also cofounded the Matter Solutions technology platform for virtual, mental, and behavioral healthcare services. She will build and manage Inflammatix's TriVerity commercial operations.
Garth previously worked as general counsel of Stereotaxis and Veran Medical Technologies. He also served as a litigator and trial attorney for Dolley Law and Bryan Cave Leighton Paisner. She will lead Inflammatix's legal and compliance functions.
CareDx: Jing Huang
CareDx has appointed Jing Huang to the newly created role of chief data and artificial intelligence officer. Huang previously served as senior VP of bioinformatics and data science at Veracyte and is currently president of the Bay Area Biotech-Pharma Statistical Workshop. She is the founding president of DahShu and chapter representative for the San Francisco Bay Area Chapter of the American Statistical Association.
For additional recent executive appointments, promotions, or departures in the omics and molecular diagnostics space, please see the People in the News page on our website.